Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 173

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer

Open access
Cottu, P., D'Hondt, V., Dureau, S., Lerebours, F., Desmoulins, I., Heudel, P.-E., Duhoux, F.P., Levy, C., Mouret-Reynier, M.-A., Dalenc, F., Frenel, J.-S., Jouannaud, C., Venat-Bouvet, L., Nguyen, S., Ferrero, J.-M., Canon, J.-L., Grenier, J., Callens, C., Gentien, D., Lemonnier, J., Vincent-Salomon, A., Delaloge, S. · 2018 · Annals of Oncology

Abstract

Background: Palbociclib is a CDK4/6 inhibitor with demonstrated efficacy and safety in combination with endocrine therapy in advanced luminal breast cancer (LBC). We evaluated the respective efficacy and safety of chemotherapy and letrozole-palbociclib (LETPAL) combination as neoadjuvant treatment in patients with high-risk LBC. Patients and methods: NeoPAL (UCBG10/4, NCT02400567) is a randomised, parallel, non-comparative phase II study. Patients with ER-positive, HER2-negative, Prosigna®-defined luminal B, or luminal A and node-positive, stage II-III breast cancer, not candidate for breast-conserving surgery, were randomly assigned to either letrozole (2.5 mg daily) and palbociclib (125 mg daily, 3 weeks/4) during 19 weeks, or to FEC100 (5FU 500 mg/m2, epirubicin 100 mg/m2, cyclophosphamide 500 mg/m2)×3 21-day courses followed by docetaxel 100 mg/m2×3 21-day courses. Primary end point was residual cancer burden (RCB 0-I rate). Secondary end points included clinical response, proliferation-based markers, and safety. Results: Overall, 106 patients were randomised [median Prosigna® ROR Score 71 (22-93)]. RCB 0-I was observed in four and eight patients in LETPAL [7.7% (95% CI 0.4-14.9)] and chemotherapy [15.7% (95% CI 5.7-25.7)] arms, respectively. Pathological complete response rates were 3.8% and 5.9%. Clinical response (75%) and breast-conserving surgery rates (69%) were similar in both arms. Preoperative Endocrine Prognostic Index 0 scores (breast cancer-specific survival) were observed in 17.6% and 8.0% of patients in LETPAL and chemotherapy arms, respectively. Safety profile was as expected, with 2 versus 17 serious adverse events (including 11 grade 4 serious AEs in the chemotherapy arm). Conclusion: LETPAL combination was associated with poor pathological response but encouraging clinical and biomarker responses in Prosigna®-defined high-risk LBC. Contemporary chemotherapy regimen was associated with poor pathological and biomarker responses, with a much less favourable safety profile. LETPAL combination might represent an alternative to chemotherapy in early high-risk LBC. Clinical Trial Number: NCT02400567.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/annonc/mdy448

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 173

Metadata

Authors
Cottu, P., D'Hondt, V., Dureau, S., Lerebours, F., Desmoulins, I., Heudel, P.-E., Duhoux, F. P., Levy, C., Mouret-Reynier, M.-A., Dalenc, F., Frenel, J.-S., Jouannaud, C., Venat-Bouvet, L., Nguyen, S., Ferrero, J.-M., Canon, J.-L., Grenier, J., Callens, C., Gentien, D., Lemonnier, J., Vincent-Salomon, A., & Delaloge, S.
Venue
Annals of Oncology
Publisher
Elsevier BV
Published
2018-12
Volume
29
Issue
12
Pages
2334-2340
ISSN
0923-7534 (ISSN-L)
OpenAlex
W2897147983
Cited by
173
References
6
FWCI
11.16
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer. https://app.cochat.ai/papers/10.1093/annonc/mdy448
The paper
Cottu, P., D'Hondt, V., Dureau, S., Lerebours, F., Desmoulins, I., Heudel, P.-E., Duhoux, F. P., Levy, C., Mouret-Reynier, M.-A., Dalenc, F., Frenel, J.-S., Jouannaud, C., Venat-Bouvet, L., Nguyen, S., Ferrero, J.-M., Canon, J.-L., Grenier, J., Callens, C., Gentien, D., . . . Delaloge, S. (2018). Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer. Annals of Oncology. https://doi.org/10.1093/annonc/mdy448

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.